Kura Oncology Inc. (NASDAQ:KURA) has been given an average broker rating score of 1.00 (Strong Buy) from the two analysts that cover the stock, Zacks Investment Research reports. Two investment analysts have rated the stock with a strong buy recommendation.
Brokers have set a 12 month consensus target price of $20.00 for the company and are predicting that the company will post ($0.41) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Kura Oncology an industry rank of 105 out of 265 based on the ratings given to related companies.
Several analysts recently issued reports on KURA shares. Zacks Investment Research upgraded Kura Oncology from a “hold” rating to a “buy” rating and set a $3.75 price target for the company in a report on Wednesday, July 13th. Oppenheimer Holdings Inc. reiterated an “outperform” rating and issued a $16.00 price target on shares of Kura Oncology in a report on Tuesday, June 21st. Finally, Leerink Swann restated an “outperform” rating and set a $15.00 target price on shares of Kura Oncology in a research note on Thursday, October 13th.
A hedge fund recently bought a new stake in Kura Oncology stock. Minerva Advisors LLC bought a new stake in shares of Kura Oncology Inc. (NASDAQ:KURA) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 361,737 shares of the company’s stock, valued at approximately $977,000. Minerva Advisors LLC owned about 1.96% of Kura Oncology as of its most recent filing with the SEC. Institutional investors own 43.63% of the company’s stock.
Kura Oncology (NASDAQ:KURA) opened at 5.35 on Friday. The firm’s market cap is $100.28 million. Kura Oncology has a 12 month low of $2.50 and a 12 month high of $25.00. The company has a 50-day moving average price of $6.16 and a 200 day moving average price of $4.23.
Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings results on Wednesday, August 10th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by $0.02. Equities research analysts anticipate that Kura Oncology will post ($1.58) EPS for the current year.
About Kura Oncology
Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kura Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.